Skip to main content

Articles

Original Research

Evaluating Outcomes in Patients with Overactive Bladder within an Integrated Healthcare Delivery System Using a Treatment Patterns Analyzer

Stakeholder Perspective

Implications of Big Data Analysis in the Real-World Setting: The Case of Overactive Bladder Treatment

Practice Management

Employer Perspectives on a Specialty Drug Step-Therapy Program Evaluation

The Challenge of Balancing Access to and Paying for New, High-Cost Cancer Therapies

Leukemia, Oncology

Refining the Use of CAR T-Cells in Patients with Acute Lymphoblastic Leukemia

Leukemia, Oncology

CAR T-Cell Therapy Produces High Response Rates in Refractory B-Cell Malignancies

Breast Cancer, Oncology

Extending Letrozole Therapy Beyond 5 Years in Early Breast Cancer Reduces Recurrence

Multiple Myeloma, Oncology

Three-Drug Regimen with Daratumumab a New Standard of Care for Relapsed or Refractory Multiple Myeloma

Atezolizumab Could Be Start of “Seismic Shift” in Metastatic Bladder Cancer Therapy

Multiple Myeloma, Oncology

Targeting CD38, Isatuximab Produces Impressive Responses in Relapsed or Refractory Multiple Myeloma

Gene-Expression Signature Validated as Prognostic Marker in Stage II Colon Cancer

Page 106 of 244
Results 1051 - 1060 of 2436